Convalescent Plasma
Convalescent plasma was experimental in COVID-19 with no randomized evidence, though it had demonstrated efficacy in approximately a dozen other viral diseases. Convalescent plasma availability improved over the course of the pandemic from…
1 sources - 4 claims
Convalescent plasma was experimental in COVID-19 with no randomized evidence, though it had demonstrated efficacy in approximately a dozen other viral diseases. Convalescent plasma availability improved over the course of the pandemic from approximately one week wait to one to two days in Southern California. Convalescent plasma from recovered COVID-19 patients provides passive antibody-mediated immunity and requires blood type matching for safe administration. Emergency use of convalescent plasma required submitting a patient clinical summary to the CDC/FDA, with authorization possible within two hours.